Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 87 Graham Number is $0.33 as of Dec. 2025, which is 75% below its 10-year median of 1.34. GuruFocus rates LJUIF with a GF Score™ of 87/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 598 Drug Manufacturers companies, SSY Group ranks better than 75.25% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-14), the stock price of SSY Group is $0.40255. SSY Group's graham number for the quarter that ended in Dec. 2025 was $0.33. Therefore, SSY Group's Price to Graham Number ratio for today is 1.20.
The historical rank and industry rank for SSY Group's Graham Number or its related term are showing as below:
LJUIF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.89 Med: 1.34 Max: 2.09
Current: 0.91
During the past 13 years, the highest Price to Graham Number ratio of SSY Group was 2.09. The lowest was 0.89. And the median was 1.34.
LJUIF's Price-to-Graham-Number is ranked better than 75.25% of 598
companies
in the Drug Manufacturers industry
Industry Median: 1.595
vs LJUIF: 0.91
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
SSY Group's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
0.40255
/
0.33
=
1.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
SSY Group Graham Number Related Terms
SSY Group Graham Number Historical Data
* Premium members only.
The historical data trend for SSY Group's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where SSY Group's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Graham Number of $0.33 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on SSY Group and its competitors. This is 75% below median its historical median of 1.34. Over the past decade, SSY Group's Graham Number has ranged from 0.89 to 2.09. According to the industry distribution chart, SSY Group ranks #148 out of 598 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is SSY Group's Graham Number too high?
SSY Group's current Graham Number of $0.33 is 75% below median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 2.09. The Drug Manufacturers industry median Graham Number is 1.60. SSY Group's value of $0.33 is 79.3% below this industry median. Based on the distribution chart, SSY Group ranks #148 out of 598 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SSY Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Graham Number compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #148 out of 598 companies for Graham Number. This places SSY Group in the top 25% of its industry — outperforming the majority of peers. The industry median Graham Number is 1.60. SSY Group's value of $0.33 is 79.3% below this benchmark. Historically, SSY Group's own Graham Number has ranged from 0.89 to 2.09 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 1.60, SSY Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.60, based on 598 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Graham Number of $0.33 is 79.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Graham Number is $0.33, which is 75% below median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Graham Number of $0.33. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Graham Number is $0.33, which is 75% below median its 10-year median of 1.34 and 79.3% below the Drug Manufacturers industry median of 1.60. SSY Group's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For SSY Group (LJUIF), the current Graham Number is $0.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Graham Number: $0.33 (75% below median its 10-year median of 1.34)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 79.3% below the Drug Manufacturers median (#148 of 598)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
87GF Score
Get the complete analysis for LJUIF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
